Possibilities of using trimetazidine in comorbid cardiovascular pathology and metabolic disorders


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. In recent years, metabolic or cytoprotective agents have been actively studied, which can increase the efficiency of oxygen utilization by the myocardium under ischemia without affecting hemodynamic parameters. The trimetazidine is most studied in this group of drugs, which is reflected in the clinical guidelines for the treatment of coronary pathology and heart failure. The frequent combination of coronary artery disease (CAD) with comorbid pathology makes it relevant to study the use of trimetazidine in such patients. Description of the clinical case. The 57-year-old man had been suffering from coronary artery disease, arterial hypertension, type 2 diabetes mellitus, and gout for a long time. In 2009, CAD was verified and coronary artery bypass grafting was performed. The reason for contacting a cardiologist was the deterioration of health in the form of shortness of breath that occurs with severe physical exertion against the background of drug therapy. Echocardiography revealed concentric left ventricle hypertrophy and 1 degree left ventricle diastolic dysfunction without increasing filling pressure with normal ejection fraction. Stress echocardiography with treadmill test verified painless myocardial ischemia. Against the background of 3-month combined anti-ischemic therapy, which included bisoprolol and trimetazidine, clinical improvement and an anti-ischemic effect were noted according to repeated stress echocardiography. Conclusion. Thus, the use of trimetazidine in the complex therapy of coronary artery disease in the presence of comorbid cardiovascular pathology and metabolic disorders can both help potentiate the antianginal effect and have a positive effect on the course of heart failure.

Full Text

Restricted Access

About the authors

Viktor S. Nikiforov

North-Western State Medical University n.a. I.I. Mechnikov

Email: viktor.nikiforov@szgmu.ru
Dr. Sci. (Med.), Prof., Dean of the Faculty of Medicine and Biology, Professor oatf the Department of Functional Diagnostics St. Petersburg, Russia

References

  1. Ferrari R., Camici P.G., Crea F., et al. Expert consensus document: A ‘diamond' approach to personalized treatment of angina. Nat Rev Cardiol. 2018;15(2):120-32. Doi: 10.1038/ nrcardio.2017.131.
  2. Knuuti J, Wijns W., Saraste A., et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020.41(3):407-77. doi: 10.1093/eurheartj/ehz425.
  3. Task Force Members, Montalescot G., Sechtem U., Achenbach S., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003. doi: 10.1093/eurheartj/eht296.
  4. Balla C, Pavasini R., Ferrari R. Treatment of Angina: Where Are We? Cardiology 2018;140:52-67. doi: 10.1159/000487936.
  5. Барбараш О.Л., Карпов Ю.А., Кашталап В.В. и др. Стабильная стенокардия. Рекомендации Российского кардиологического общества 2020. Российский кардиологический журнал. 2020; 25(11): 201-250. [Barbarash O.L., Karpov Yu.A., Kashtalap V.V et al. Stable angina pectoris. Recommendations of the Russian Cardiological Society 2020. Rossiiskii kardiologicheskii zhurnal=Russ J Cardiol. 2020; 25(11): 201-50 (In Russ.)]. doi: 10.15829/1560-4071-2020-4076.
  6. Rossini E, Biscetti F., Rando M.M. et al. Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter? Int J Mol Sci. 2022;23(16):9326. Doi: 10.3390/ ijms23169326.
  7. Никифоров B.C. Реология крови в процессе терапии больных ишемической болезнью сердца. Регионарное кровообращение и микроциркуляция. 2002;1(1):60-5.
  8. Никифоров В.С. Вязкость крови как мишень терапевтического воздействия при сердечно-сосудистой патологии. Фарматека. 2015;13(306):59-63
  9. Suljic U., Prnjavorac B, Bego T., et al. The role of metabolic therapy with trimetazidine in effort tolerance in patients with ischemic heart disease. Med Glas (Zenica). 2018;15(2):109-14. doi: 10.17392/965-18.
  10. Dezsi C.A. Trimetazidine in Practice: Review of the Clinical and Experimental Evidence. Am J Ther. 2016;23(3):e871-9. Doi: 10.1097/ MJT.0000000000000180.
  11. Карпов Ю.А. Лечение пациентов со стабильной ишемической болезнью сердца: алгоритм анти-ангинальной терапии. Атмосфера. Новости кардиологии. 2021;(1):18-29.
  12. Чельцов В.В. Можно ли предупредить метаболическое ремоделирование: возможности применения триметазидина. Терапия. 2017; 7(17): 116-22.
  13. Жиров И.В., Осмоловская Ю.Ф., Терещенко С.Н. Триметазидин в лечении хронической сердечной недостаточности. Кардиология. 2016;56(1):79-85.
  14. Rotariu D., Babes E.E., Tit D.M., et al. Oxidative stress - Complex pathological issues concerning the hallmark of cardiovascular and metabolic disorders. Biomed Pharmacother. 2022;152:113238. Doi: 10.1016/j. biopha.2022.113238.
  15. Свистов А.С., Филиппов А.Е., Никифоров В.С., Никитин А.Э. Ишемическая болезнь сердца: диагностика и лечение жизнеспособного миокарда. СПб: ВМедА, 2004. 24 с.
  16. Никифоров В.С., Никитин А.Э., Тыренко В.В., Свистов А.С. Ишемическая дисфункция миокарда. М.: АПКиППРО. 2005. 102 с.
  17. Полякова О.А., Чочуа А.А., Головина О.В. и др. Возможности применения триметазидина в лечении пациентов с ишемической болезнью сердца и хронической сердечной недостаточностью. Фарматека. 2021;28(13):54-62.
  18. Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и др. Клинические рекомендации ОССН - РКО -РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(S6):1-164.
  19. Ponikowski P., Voors A.A., Anker SD., et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128.
  20. Deichl A., Wachter R., Edelmann F.Comorbidities in heart failure with preserved ejection fraction. Herz. 2022;47(4):301-7. Doi: 10.1007/ s00059-022-05123-9.
  21. Кочеткова И.В., Черных Т.М., Панюшкина Г.М. Опыт применения триметазидина у пациентов с коморбидной патологией. Российский кардиологический журнал. 2018,(3):37-42.
  22. Lin Y., Wang Z.L., Yan M., et al. Effect of Trimetazidine on Diabetic Patients with Coronary Heart Diseases: A Meta-Analysis of Randomized, Controlled Trials. Chin Med Sci J. 2020;35(3):226-38. doi: 10.24920/003678.
  23. Meiszterics Z., Konyi A., Hild G., et al. Effectiveness and safety of anti-ischemic trimetazidine in patients with stable angina pectoris and Type 2 diabetes. J Comp Eff Res. 2017;6(8):649-57 doi: 10.2217/cer-2017-0011.
  24. Borghetti G, von Lewinski D., Eaton D.M., et al. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. Front Physiol. 2018; 9:1514. Doi: 10.3389/ fphys.2018.01514.
  25. Glezer M. CHOICE-2 study investigators. Trimetazidine and Bisoprolol to Treat Angina in Symptomatic Patients: Post Hoc Analysis From the CHOICE-2 Study. CardiolTher. 2021;10(1):161-73. doi: 10.1007/s40119-020-00202-6
  26. Salvatore T., Galiero R., Caturano A., et al. Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options. Biomedicines. 2022;10(9):2274. doi: 10.3390/biomedicines10092274

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies